Recently, trastuzumab deruxtecan was shown to be effective for HER2 low (2+ without gene amplification or 1 +) or ultra-low (score 0 with faint or incomplete membrane staining in less than 10% of tumor cells) breast cancer in clinical trials [23, 24]. This evidence concerns the gene ERBB2 and breast carcinoma.